VK-2019

Biorbyt

VK-2019 [2044520-06-9]

10

2044520-06-9

Research Use Only

C29H25NO4

451.513108

VK-2019 is a selective EBNA1 inhibitor. VK-2019 was developed as a highly specific inhibitor of EBNA1 DNA binding activity and is currently in phase 1 development as a treatment for EBV-associated carcinomas. EBNA1 is an Epstein Barr virus (EBV) protein expressed in all EBV-associated cancers. EBNA1 plays a critical role in the replication and maintenance of EBV episomes in latently infected cells.

C(O)(=O)C1=CC=CC(C#CC2=CC=C(COC3CCOCC3)C=C2)=C1C1=CC2=C(C=C1)C=CN2

12352200